-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anticoagulant drugs refer to drugs that prevent blood coagulation, and are mainly used for the prevention and treatment of thromboembolic diseases such as deep vein thrombosis, cerebral infarction and myocardial infarction
.
Currently, commonly used clinical anticoagulant drugs include low molecular weight heparin, factor Xa inhibitors, vitamin K antagonists and antiplatelet drugs
.
Among them, apixaban is a reversible and highly selective direct factor Xa inhibitor and belongs to a new type of oral anticoagulant drug
.
Compared with other commonly used anticoagulants, apixaban has good safety and tolerance, can effectively reduce the incidence of stroke and systemic embolism, and does not increase the risk of bleeding, so it has received much attention in the industry.
high
.
According to the information from the State Food and Drug Administration, Chengdu Baiyu Pharmaceutical Co.
, Ltd.
has entered the stage of administrative approval for the anticoagulant "Apixaban Tablets", which is a generic type 4 drug
.
Apixaban was jointly developed by Bristol-Myers Squibb and Pfizer and is mainly used for the prevention of venous thromboembolic events (VTE) in adult patients undergoing elective hip or knee replacement
.
The product was first approved for marketing in the EU in 2011, with specifications including 2.
5mg and 5mg, and was subsequently approved for marketing by FDA and PMDA in December 2012
.
In recent years, the global sales of apixaban have shown a rapid upward trend, breaking through US$1 billion in 2015 and reaching US$10 billion in 2021
.
In the domestic market, the original research drug of this product was approved to enter the Chinese market in January 2013
.
According to the data from Minet.
com, the annual sales data of sample hospitals in China from 2018 to 2020 showed that the sales of apixaban tablets were 31.
75 million yuan, 53.
94 million yuan, and 110 million yuan respectively
.
Entering 2021, affected by centralized procurement, the growth rate of this product will decline in the first half of 2021
.
However, some people in the industry believe that with the intensification of the aging population in China, the aging population has more preoperative comorbidities, and anticoagulation therapy is required after joint replacement.
Coupled with the improvement of people's requirements for quality of life, the number of artificial joint replacements in China is increasing.
It is expected to grow rapidly, and the market still has great potential
.
The author also learned that due to the high price of apixaban, the product has entered the new version of the medical insurance catalogue in 2017 and was included in the medical insurance category B drug, which reduces the burden of drug costs for patients, and is expected to be also expected in the domestic market.
Ushered in the situation of rapid sales growth
.
Judging from the list of companies currently entering the bureau, there are more than 20 domestic companies that have production approvals for apixaban tablets, including Qilu Pharmaceutical, Hunan Qianjin Xiangjiang Pharmaceutical, Zhejiang Hisun Pharmaceutical, Jiangsu Qingfeng Pharmaceutical, and Chia Tai Tianqing Pharmaceutical.
, Guangdong Dongguang Pharmaceutical, Sichuan Kelun Pharmaceutical,
etc.
In addition, judging from the situation of the reviewed companies, the rivaroxaban tablets of Chengdu Baiyu Pharmaceutical have been approved for production and are deemed to have passed the review.
In addition, there are more than 20 companies whose apixaban tablets have passed or are deemed to have passed the consistency evaluation.
, including Hisun Pharmaceutical, Yangzijiang, CSPC, Qilu Pharmaceutical, Kelun, Haosen and other large enterprises
.
Overall, the domestic rivaroxaban tablet market competition is accumulating day by day
.
The industry pointed out that for the generic drug of apixaban, a blockbuster product, the country is already in a situation of competition for hegemony, and it is uncertain which pharmaceutical company can win in the domestic anticoagulant market in the future
.
"However, generally speaking, one of the major advantages of generic drugs of domestic local pharmaceutical companies is the price and channel advantages of products.
Companies with advantages in these aspects will benefit from future competition with a high probability
.
" Disclaimer: In any case The information or opinions expressed in this article do not constitute investment advice to anyone
.
.
Currently, commonly used clinical anticoagulant drugs include low molecular weight heparin, factor Xa inhibitors, vitamin K antagonists and antiplatelet drugs
.
Among them, apixaban is a reversible and highly selective direct factor Xa inhibitor and belongs to a new type of oral anticoagulant drug
.
Compared with other commonly used anticoagulants, apixaban has good safety and tolerance, can effectively reduce the incidence of stroke and systemic embolism, and does not increase the risk of bleeding, so it has received much attention in the industry.
high
.
According to the information from the State Food and Drug Administration, Chengdu Baiyu Pharmaceutical Co.
, Ltd.
has entered the stage of administrative approval for the anticoagulant "Apixaban Tablets", which is a generic type 4 drug
.
Apixaban was jointly developed by Bristol-Myers Squibb and Pfizer and is mainly used for the prevention of venous thromboembolic events (VTE) in adult patients undergoing elective hip or knee replacement
.
The product was first approved for marketing in the EU in 2011, with specifications including 2.
5mg and 5mg, and was subsequently approved for marketing by FDA and PMDA in December 2012
.
In recent years, the global sales of apixaban have shown a rapid upward trend, breaking through US$1 billion in 2015 and reaching US$10 billion in 2021
.
In the domestic market, the original research drug of this product was approved to enter the Chinese market in January 2013
.
According to the data from Minet.
com, the annual sales data of sample hospitals in China from 2018 to 2020 showed that the sales of apixaban tablets were 31.
75 million yuan, 53.
94 million yuan, and 110 million yuan respectively
.
Entering 2021, affected by centralized procurement, the growth rate of this product will decline in the first half of 2021
.
However, some people in the industry believe that with the intensification of the aging population in China, the aging population has more preoperative comorbidities, and anticoagulation therapy is required after joint replacement.
Coupled with the improvement of people's requirements for quality of life, the number of artificial joint replacements in China is increasing.
It is expected to grow rapidly, and the market still has great potential
.
The author also learned that due to the high price of apixaban, the product has entered the new version of the medical insurance catalogue in 2017 and was included in the medical insurance category B drug, which reduces the burden of drug costs for patients, and is expected to be also expected in the domestic market.
Ushered in the situation of rapid sales growth
.
Judging from the list of companies currently entering the bureau, there are more than 20 domestic companies that have production approvals for apixaban tablets, including Qilu Pharmaceutical, Hunan Qianjin Xiangjiang Pharmaceutical, Zhejiang Hisun Pharmaceutical, Jiangsu Qingfeng Pharmaceutical, and Chia Tai Tianqing Pharmaceutical.
, Guangdong Dongguang Pharmaceutical, Sichuan Kelun Pharmaceutical,
etc.
In addition, judging from the situation of the reviewed companies, the rivaroxaban tablets of Chengdu Baiyu Pharmaceutical have been approved for production and are deemed to have passed the review.
In addition, there are more than 20 companies whose apixaban tablets have passed or are deemed to have passed the consistency evaluation.
, including Hisun Pharmaceutical, Yangzijiang, CSPC, Qilu Pharmaceutical, Kelun, Haosen and other large enterprises
.
Overall, the domestic rivaroxaban tablet market competition is accumulating day by day
.
The industry pointed out that for the generic drug of apixaban, a blockbuster product, the country is already in a situation of competition for hegemony, and it is uncertain which pharmaceutical company can win in the domestic anticoagulant market in the future
.
"However, generally speaking, one of the major advantages of generic drugs of domestic local pharmaceutical companies is the price and channel advantages of products.
Companies with advantages in these aspects will benefit from future competition with a high probability
.
" Disclaimer: In any case The information or opinions expressed in this article do not constitute investment advice to anyone
.
